These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28494813)

  • 1. Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations.
    Nasca A; Rizza T; Doimo M; Legati A; Ciolfi A; Diodato D; Calderan C; Carrara G; Lamantea E; Aiello C; Di Nottia M; Niceta M; Lamperti C; Ardissone A; Bianchi-Marzoli S; Iarossi G; Bertini E; Moroni I; Tartaglia M; Salviati L; Carrozzo R; Ghezzi D
    Orphanet J Rare Dis; 2017 May; 12(1):89. PubMed ID: 28494813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1.
    Lee J; Jung SC; Hong YB; Yoo JH; Koo H; Lee JH; Hong HD; Kim SB; Chung KW; Choi BO
    Mol Med Rep; 2016 Jul; 14(1):33-40. PubMed ID: 27150940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation survey of the optic atrophy 1 gene in 193 Chinese families with suspected hereditary optic neuropathy.
    Chen Y; Jia X; Wang P; Xiao X; Li S; Guo X; Zhang Q
    Mol Vis; 2013; 19():292-302. PubMed ID: 23401657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies.
    Yu-Wai-Man P; Shankar SP; Biousse V; Miller NR; Bean LJ; Coffee B; Hegde M; Newman NJ
    Ophthalmology; 2011 Mar; 118(3):558-63. PubMed ID: 21036400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier.
    Bonifert T; Karle KN; Tonagel F; Batra M; Wilhelm C; Theurer Y; Schoenfeld C; Kluba T; Kamenisch Y; Carelli V; Wolf J; Gonzalez MA; Speziani F; Schüle R; Züchner S; Schöls L; Wissinger B; Synofzik M
    Brain; 2014 Aug; 137(Pt 8):2164-77. PubMed ID: 24970096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leigh-like neuroimaging features associated with new biallelic mutations in OPA1.
    Rubegni A; Pisano T; Bacci G; Tessa A; Battini R; Procopio E; Giglio S; Pasquariello R; Santorelli FM; Guerrini R; Nesti C
    Eur J Paediatr Neurol; 2017 Jul; 21(4):671-677. PubMed ID: 28442211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fourteen novel OPA1 mutations in autosomal dominant optic atrophy including two de novo mutations in sporadic optic atrophy.
    Baris O; Delettre C; Amati-Bonneau P; Surget MO; Charlin JF; Catier A; Derieux L; Guyomard JL; Dollfus H; Jonveaux P; Ayuso C; Maumenee I; Lorenz B; Mohammed S; Tourmen Y; Bonneau D; Malthièry Y; Hamel C; Reynier P
    Hum Mutat; 2003 Jun; 21(6):656. PubMed ID: 14961560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy.
    Nakamura M; Lin J; Ueno S; Asaoka R; Hirai T; Hotta Y; Miyake Y; Terasaki H
    Ophthalmology; 2006 Mar; 113(3):483-488.e1. PubMed ID: 16513463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy.
    Caporali L; Magri S; Legati A; Del Dotto V; Tagliavini F; Balistreri F; Nasca A; La Morgia C; Carbonelli M; Valentino ML; Lamantea E; Baratta S; Schöls L; Schüle R; Barboni P; Cascavilla ML; Maresca A; Capristo M; Ardissone A; Pareyson D; Cammarata G; Melzi L; Zeviani M; Peverelli L; Lamperti C; Marzoli SB; Fang M; Synofzik M; Ghezzi D; Carelli V; Taroni F
    Ann Neurol; 2020 Jul; 88(1):18-32. PubMed ID: 32219868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective mitochondrial adenosine triphosphate production in skeletal muscle from patients with dominant optic atrophy due to OPA1 mutations.
    Lodi R; Tonon C; Valentino ML; Manners D; Testa C; Malucelli E; La Morgia C; Barboni P; Carbonelli M; Schimpf S; Wissinger B; Zeviani M; Baruzzi A; Liguori R; Barbiroli B; Carelli V
    Arch Neurol; 2011 Jan; 68(1):67-73. PubMed ID: 20837821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and late-onset optic atrophy due to a novel OPA1 mutation leading to a mitochondrial coupling defect.
    Nochez Y; Arsene S; Gueguen N; Chevrollier A; Ferré M; Guillet V; Desquiret V; Toutain A; Bonneau D; Procaccio V; Amati-Bonneau P; Pisella PJ; Reynier P
    Mol Vis; 2009; 15():598-608. PubMed ID: 19325939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations.
    Schaaf CP; Blazo M; Lewis RA; Tonini RE; Takei H; Wang J; Wong LJ; Scaglia F
    Mol Genet Metab; 2011 Aug; 103(4):383-7. PubMed ID: 21636302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy.
    Thiselton DL; Alexander C; Taanman JW; Brooks S; Rosenberg T; Eiberg H; Andreasson S; Van Regemorter N; Munier FL; Moore AT; Bhattacharya SS; Votruba M
    Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1715-24. PubMed ID: 12036970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutations of the OPA1 gene in Chinese dominant optic atrophy.
    Yen MY; Wang AG; Lin YC; Fann MJ; Hsiao KJ
    Ophthalmology; 2010 Feb; 117(2):392-6.e1. PubMed ID: 19969356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel AFG3L2 mutation close to AAA domain leads to aberrant OMA1 and OPA1 processing in a family with optic atrophy.
    Baderna V; Schultz J; Kearns LS; Fahey M; Thompson BA; Ruddle JB; Huq A; Maltecca F
    Acta Neuropathol Commun; 2020 Jun; 8(1):93. PubMed ID: 32600459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-system neurological disease is common in patients with OPA1 mutations.
    Yu-Wai-Man P; Griffiths PG; Gorman GS; Lourenco CM; Wright AF; Auer-Grumbach M; Toscano A; Musumeci O; Valentino ML; Caporali L; Lamperti C; Tallaksen CM; Duffey P; Miller J; Whittaker RG; Baker MR; Jackson MJ; Clarke MP; Dhillon B; Czermin B; Stewart JD; Hudson G; Reynier P; Bonneau D; Marques W; Lenaers G; McFarland R; Taylor RW; Turnbull DM; Votruba M; Zeviani M; Carelli V; Bindoff LA; Horvath R; Amati-Bonneau P; Chinnery PF
    Brain; 2010 Mar; 133(Pt 3):771-86. PubMed ID: 20157015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPA1 analysis in an international series of probands with bilateral optic atrophy.
    Liskova P; Tesarova M; Dudakova L; Svecova S; Kolarova H; Honzik T; Seto S; Votruba M
    Acta Ophthalmol; 2017 Jun; 95(4):363-369. PubMed ID: 27860320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic stroke in a patient with bi-allelic OPA1 mutations.
    Zerem A; Yosovich K; Rappaport YC; Libzon S; Blumkin L; Ben-Sira L; Lev D; Lerman-Sagie T
    Metab Brain Dis; 2019 Aug; 34(4):1043-1048. PubMed ID: 30972688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy controls the pathogenicity of OPA1 mutations in dominant optic atrophy.
    Kane MS; Alban J; Desquiret-Dumas V; Gueguen N; Ishak L; Ferre M; Amati-Bonneau P; Procaccio V; Bonneau D; Lenaers G; Reynier P; Chevrollier A
    J Cell Mol Med; 2017 Oct; 21(10):2284-2297. PubMed ID: 28378518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent OPA1 mutation and chromosome 3q deletion leading to Behr syndrome: a case report.
    Zeng T; Liao L; Guo Y; Liu X; Xiong X; Zhang Y; Cen S; Li H; Wei S
    BMC Pediatr; 2020 Sep; 20(1):420. PubMed ID: 32883255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.